Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears.
Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J. Szarewski A, et al. Among authors: ambroisine l. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3033-42. doi: 10.1158/1055-9965.EPI-08-0508. Epub 2008 Oct 28. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18957520
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.
Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, Berney DM, Møller H, Reuter VE, Scardino P, Cuzick J, Ragavan N, Singh PB, Martin FL, Butler CM, Cooper CS, Swain A; Transatlantic Prostate Group. Thomsen MK, et al. Among authors: ambroisine l. Cancer Res. 2010 Feb 1;70(3):979-87. doi: 10.1158/0008-5472.CAN-09-2370. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103652 Free PMC article.
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group; Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. LHRH-agonists in Early Breast Cancer Overview group, et al. Among authors: ambroisine l. Lancet. 2007 May 19;369(9574):1711-23. doi: 10.1016/S0140-6736(07)60778-8. Lancet. 2007. PMID: 17512856
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS; Transatlantic Prostate Group. Reid AH, et al. Among authors: ambroisine l. Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26. Br J Cancer. 2010. PMID: 20104229 Free PMC article.
Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.
Kudahetti SC, Fisher G, Ambroisine L, Prowse D, Kattan MW, Foster CS, Møller H, Oliver T, Fletcher A, Cooper C, Reuter V, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group. Kudahetti SC, et al. Among authors: ambroisine l. Pathology. 2010;42(6):519-23. doi: 10.3109/00313025.2010.508788. Pathology. 2010. PMID: 20854069
31 results